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Introduction: The advent of tyrosine kinase inhibitors has produced 5-year survival of 90 + % for chronic myelocytic
leukemia (CML) patients in clinical trials. However, population level survival has been lower, especially in older
patients. Here, we examine survival of patients with CML in Germany and compare it to survival of patients in the
United States (US).
Methods: Data were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11
cancer registries in Germany. Patients 15–69 years old diagnosed with CML were included in the analysis. Period
analysis for 2002–2006 was used to provide the most up-to-date possible estimates of five-year relative survival.
Results: Five-year relative survival was 68.7% overall in Germany and 72.7% in the US. Survival was higher in the US
for all age groups except for ages 15–39 years, but the difference was only statistically significant for ages 50–
59 years (at 67.5% vs 77.7% in Germany and the US, respectively). Survival decreased with age, ranging from 83.1%
and 81.9%, respectively, in Germany and the US for patients 15–39 years old to 54.2% and 54.5%, respectively, in
patients 65–69 years old. Survival increased between 2002 and 2006 by 12.0% points in Germany and 17.1% points
in the US.
Conclusions: Five-year survival estimates were higher in the US than in Germany overall, but the difference was
only significant for ages 50–59 years. Survival did not equal that seen in clinical trials for either country, but strong
improvement in survival was seen between 2002 and 2006.
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Treatment for chronic myelocytic leukemia (CML) has
changed dramatically over the past several decades, es-
pecially in the early 21st century. Prior to the late 1980s,
treatment was limited to chemotherapy, with a poor
chance of 5-year survival for any patient subpopulation
[1-3]. In the late 1980s-1990s, newer treatment options,* Correspondence: pultedi@gmail.com
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reproduction in any medium, provided the orincluding interferon-α [4,5] and hematopoietic stem cell
transplant (HSCT) [6,7] became available, improving
survival for some subpopulations. However, each of
these treatment options is limited in its scope.
Interferon-α is poorly tolerated in many patients, and
only a subset of patients will respond. HSCT can be used
only if a donor is available and, especially in the early
years of HSCT development, only in younger and
healthier patients. In 2001, the first targeted treatment
for CML, imatinib, a tyrosine kinase inhibitor (TKI) [8],
became available in Germany [9] and the US [10]. This
medication was well tolerated and provided complete re-
sponse in the majority of patients. Additionally, it can bed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toxicity. Clinical trials of CML patients in chronic phase
treated with imatinib showed 5-year survival rates of
nearly 90% and up to 95% when only CML related
events were considered [11,12]. Newer tyrosine kinase
inhibitors have shown even higher response rates and
better survival, often with less toxicity [13,14].
Estimates of CML patient survival in the overall popu-
lation have shown dramatic increases, especially for chil-
dren and younger adults. However, survival has lagged
in older adults. Additionally, the majority of population-
level survival estimates for CML patients are derived
from studies of the Surveillance, Epidemiology, and End
Results (SEER) database in the United States [15-17] or
from small series within Europe [18-20], with no prior
studies concentrating specifically on CML patient sur-
vival in Germany. In the past, examination of population
level survival with rare cancers in Germany has been
hampered by lack of high quality data from a unified
database. Recently, a collaborative project funded by the
German Cancer Aid was set up between 11 population
based German cancer registries and the German Cancer
Research Center to provide comprehensive data on can-
cer survival in Germany [21]. This collaboration allows
examination of detailed survival with rare cancers such
as CML.
Here, we examine survival of patients diagnosed with
CML in Germany between 1997 and 2006. Because age
is an important prognostic factor in CML, we exam-
ine survival by age group as well as overall. Compari-
son is made to survival in the US using the SEER13
database.Table 1 Number of cases and percentage of cases diagnosed







Bavaria 8.13 2002-2006 285
Brandenburg 2.55 1997-2006 219
Bremen 0.66 1998-2006 53
Hamburg 1.75 1997-2006 160
Mecklenburg-Vorpommern 1.69 1997-2006 173
Lower Saxony 7.98 2001-2006 435
North Rhine-Westphalia 2.62 1997-2004 159
Rhineland-Palatinate 0.52 1998-2006 25
Saarland 1.04 1997-2006 94
Saxony 4.25 1997-2006 352
Schleswig-Holstein 1.85 1999-2006 157
Total 33.04 2112
a = death certificate only.Methods
Data sources
A detailed description of the cancer registries from
which data were obtained has been published previously
[21]. Briefly, data were extracted from 11 population-
based cancer registries throughout Germany, repre-
senting a total base population of 33 million people
(Table 1). Patients age 15 or older with a primary diag-
nosis of typical, BCR-ABL positive CML (ICD-10 code
92.1) between 1997 and 2006 and with vital status follow
up through December, 2006 were included. For some
registries, data were available starting from later years
only. Because of data quality issues for patients age
70 years and older, in particular high proportions of
cases notified by death certificate only (DCO), only data
for patients 15–69 years old were included.
In order to compare population-level survival for CML
patients in Germany with survival in the United States
(US), data from the Surveillance, Epidemiology, and End
Results (SEER13) database were analyzed [22]. The same
inclusion criteria as for patients from the German cancer
registries were applied for the same time period. The
SEER13 database includes data from 13 regional cancer
centers in the US, covering a population of about 39
million people. Centers are chosen for inclusion based
on their high quality and epidemiologically interesting
population groups. The SEER population is consid-
ered to be similar to the general US population with
respect to most sociodemographic characteristics, al-
though it may be more affluent than average and may
have slightly higher than average survival for some











15.4 0 241 55.0 100.0
13.7 1 189 56.0 99.4
15.1 0 45 62.0 95.6
5.6 0 151 53.0 100.0
11.0 0 154 56.5 99.4
8.7 0 397 57.0 96.4
8.2 0 146 54.0 100.0
12.0 0 22 61.0 100.0
1.1 0 93 58.0 100.0
19.6 0 283 58.0 98.9
19.1 0 127 58.0 100.0
12.5 1 1848 56.0 98.8
Table 2 Percentages of cases diagnosed by death








Table 3 Five year relative survival of patients diagnosed
with CML in Germany and in the US
Germany US
Age N RS SE N RS SE Diff P (Model)
15-39 324 83.1 3.0 818 81.9 2.0 +1.2 0.9403
40-49 328 78.0 3.4 680 82.8 2.2 −4.8 0.1777
50-59 423 67.5 3.5 697 77.7 2.6 −10.2 0.0018
60-64 361 65.3 3.8 340 70.3 4.1 −5 0.2065
65-69 412 54.2 4.0 375 54.5 4.2 −0.3 0.5093
Overall 1848 68.7 1.6 2910 72.7a 1.5 −4 0.0036
a = age adjusted using the percentage of cases in each age group in Germany.
N = Number of cases.
RS = 5-year relative survival.
SE = Standard Error.
Diff = Difference between survival in Germany and the US.
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Five-year relative survival estimates for the time period
2002–2006 were calculated using period analysis [24].
Period analysis, first introduced in 1996 [25], provides
more up-to-date survival estimates than traditional co-
hort based analysis. In particular, it has been shown by
extensive empirical evaluation, that period estimates of
5-year relative survival for a given period quite closely
predict 5-year relative survival later observed for patients
diagnosed during the period of interest [26,27]. In order
to ensure comparability of survival estimates between
both countries, age-adjusted survival estimates were
derived by computing weighted sums of age-specific sur-
vival estimates using weights according to the propor-
tion of cases in the age groups (15–39, 40–49, 50–59,
60–64, and 65–69) in Germany. Because survival of
patients with CML varies with age and gender [28], we
examined survival by major age groups as above and
by gender. Differences in survival between men and
women, as well as between patients in Germany and the
US, were tested for statistical significance, overall and by
single age groups, using model-based period analysis
[29]. Additionally, model-based period analysis [29] was
also employed to estimate changes in 5-year relative
survival within the 2002–2006 period.
Relative survival was calculated as the ratio of actual
survival to expected survival. Expected survival was esti-
mated according to the Ederer II method [30] using
national life tables. For German patients, life tables
stratified by age, sex, and calendar year were obtained
from the German Federal Statistical Office. Relative sur-
vival for the US patients was calculated using US sex-,
age-, calendar year-, and race-specific life tables pub-
lished by the Center for Disease Control (CDC) [31].
All calculations were carried out using SAS software
(version 9.2), using macros developed for standard and
modelled period analysis [27,32].
Results
Overall, 2112 patients with CML diagnosed between the
ages 15 and 69 years were identified in the German
cooperative database, of whom 12.5% were reported by
DCO, leaving 1848 for survival analysis (Table 1). During
the same time period, 2919 cases, including 9 DCO
cases (0.3%), were identified in the SEER13 database,
leaving 2910 cases for analysis. The percentages of DCO
cases by age for Germany and the US are described in
Table 2.
Overall five year relative survival was 68.7% in
Germany and 72.7% in the US (Table 3). There was a
trend towards higher survival for younger patients (15–
39 years old) in Germany, although the difference did
not reach statistical significance. For all other age
groups, survival was higher in the US, although thedifference reached statistical significance only for pa-
tients 50–59 years old for whom survival was 10.2 per-
centage points higher in the US (Table 3). Because there
was some concern that the high rate of DCO cases
among some registries may bias results, an analysis was
performed excluding registries with more than 12% of
cases being reported by DCO. The results did not
materially change with the exclusion of high DCO regis-
tries, except for patients age 65–69, for whom the 5-year
relative survival in Germany was lower than that calcu-
lated using all registries (Table 4).
Five year relative survival was higher for women than
for men in all age groups in both Germany and the US,
at 65.5% and 69.7% overall for men in Germany and the
US, respectively, and 72.8% and 77% overall for women
in Germany and the US, respectively (Table 5). For men,
there was a trend towards higher survival in the US, with
the exception of patients age 65–69, where both survival
estimates were nearly equal. However, the finding of
higher survival in the US was statistically significant (p <
0.05) only for the overall survival estimate (Table 5). For
women, there was a trend towards higher survival in
Germany for ages 15–39 years with a difference of +6.8
percentage points, but it did not reach statistical
Table 4 Five year relative survival of patients diagnosed
with CML in Germany and in the US, excluding registries
with more than 12% of cases reported by DCO
Germany US
Age N RS SE N RS SE Diff P (Model)
15-39 175 81.0 4.6 818 81.9 2.0 −0.9 0.7043
40-49 176 77.0 4.8 680 82.8 2.2 −5.8 0.2409
50-59 218 68.6 5.0 697 77.7 2.6 −9.1 0.0310
60-64 174 61.0 5.5 340 70.3 4.1 −5.3 0.0623
65-69 220 45.3 5.7 375 54.5 4.2 −9.2 0.0009
Overall 963 65.6 2.3 2910 72.7a 1.5 −7.1 0.7043
a = age adjusted using the percentage of cases in each age group in Germany.
N = Number of cases.
RS = 5-year relative survival.
SE = Standard Error.
Diff = Difference between survival in Germany and the US.
Table 6 Survival of patients diagnosed with CML in
Germany and the US, 2002 versus 2006
2002 2006
Age group RS SE RS SE Diff P (Model)
Germany
15-59 67.1 4.1 81.7 2.7 +14.6 0.0089
60-69 54.7 5.2 63.2 4.2 +8.5 0.2560
Overall 61.8 3.1 73.8 2.4 +12.0 0.0071
US
15-59 74.3 2.6 86.5 1.9 +12.2 0.0010
60-69 49.4 5.2 73.7 4.4 +24.3 0.0027
Overall a 63.2 2.6 80.3 2.1 +17.1 <0.0001
a = age adjusted using the percentage of cases in each age group in Germany.
RS = 5-year relative survival.
SE = Standard Error.
Diff = Difference between survival in Germany and the US.
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longer survival in the US. The difference was most
pronounced and statistically significant for age group
50–59 years at −14.6 percentage (Table 5).
Survival improved between 2002 and 2006 in both
Germany and the US (Table 6). In the US, the increase
was statistically significant for both younger patients
(15–59 years old) and middle-aged patients (60–69 years
old), but was greater for middle-aged patients (Table 6).
In Germany, the increase was statistically significant only
for younger patients (+14.6 percentage points), althoughTable 5 Five year relative survival of patients diagnosed
with CML in Germany and the US for (a) men and (b)
women, 2002–06
Germany US
Age N RS SE N RS SE Diff P (Model)
a. Men
15-39 207 78.4 4.1 528 80.6 2.6 −2.2 0.5275
40-49 184 76.5 4.5 383 80.5 3.1 −4 0.3275
50-59 234 65.1 5.1 401 73.9 3.5 −8.8 0.0575
60-64 207 61.5 5.6 191 68.8 5.5 −7.3 0.3367
65-69 242 50.3 5.5 204 48.9 5.7 +1.4 0.6480
Overall 1074 65.5 2.3 1707 69.7a 2.0 −4.2 0.0273
b. Women
15-39 117 91.2 4.0 290 84.4 3.1 +6.8 0.2632
40-49 144 80.1 5.0 297 85.8 3.1 −5.7 0.3460
50-59 189 69.6 4.8 296 84.0 3.6 −14.6 0.0050
60-64 154 69.1 5.3 149 71.7 6.1 −2.6 0.4252
65-69 170 59.2 5.5 171 61.4 6.1 −2.2 0.6316
Overall 774 72.8 2.3 1203 77.0a 2.1 −4.2 0.0453
a = age adjusted using the percentage of cases in each age group in Germany.
N = Number of cases.
RS = 5-year relative survival.
SE = Standard Error.
Diff = Difference between survival in Germany and the US.a trend towards increased survival was also observed for
middle-aged patients (Table 6).
Discussion
Treatment for CML has changed substantially over the
first few years of the 21st century. Until 2001, the stand-
ard treatment for CML was hematopoietic stem cell
transplant, if possible, and interferon-α with hydroxy-
urea and other chemotherapeutic agents used in cases of
poor response or intolerance to interferon or lack of
donor or inability to tolerate transplant. In May, 2001,
imatinib, the first TKI specifically developed to block the
activity of the Bcr-abl protein, was approved for use in
CML in the United States [9]. It was approved for use in
Germany in November, 2001 as well [8] and quickly
gained acceptance as the new standard of care. The ini-
tial study of imatinib in chronic phase CML showed re-
sponse rates of 90% or higher for recipients [11].
Subsequent studies of other TKIs have also shown very
high response rates and durable remissions [12,13].
However, population level data have generally shown a
discrepancy between the results obtained in these trials
and survival in the general population, especially in older
patients [3,15,16]. Although use of imatinib in older pa-
tients has been shown to be safe and effective in clinical
trials [33,34], its use in older patients in the general
population has lagged [17].
The improvement in survival between 2002 and 2006
may be partly driven by increased uptake of imatinib in
that time period and possibly to initiation of the medica-
tion sooner after diagnosis, specifically use on patients
still in the chronic phase where it is most effective. Al-
though there is little data directly addressing uptake of
specific medications in different countries, one study
suggests that there was rapid uptake of imatinib in both
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sicians in the US and Europe (including, but not limited
to, Germany) regarding practice in 2005–06 showed that
physicians surveyed in each location chose TKI for first
line therapy in most situations, including treatment of
older patients. Overall, major differences in practice
were not observed. However, use of pre-TKI options
after failure of first line TKI in older patients (i.e. inter-
feron or hydroxyurea) was more common among
European physicians, possibly suggesting a lower uptake
of second generation TKI, especially for older patients
[36]. It should be noted that more physicians in Europe
were familiar with testing for mutations in Bcr-abl that
lead to TKI resistance, possibly explaining the differ-
ences in therapy plans observed. Since this study did not
specifically examine treatment patterns in Germany, it is
not possible to say whether the results are reflective of
standard practice in Germany versus other parts of
Europe. Additionally, physicians who responded to the
survey may not represent typical practice as they are to
some degree self-selected.
Because period analysis of survival in 2002–2006 uses
data from patients diagnosed as early as 1997, the extra
six months of generally available imatinib in 2001 may
also give the US an advantage in terms of survival esti-
mates, especially in, but not limited to, earlier time
periods. Additional factors, including later diagnosis,
differences in tumor biology, and random fluctuation of
response in a rare disease should also be considered. A
larger percentage of German patients were diagnosed at
age 60–69, which may suggest delay in diagnosis in
Germany or possibly differences in tumor biology. How-
ever, it should be noted that the median age of the popu-
lation in Germany is older than in the US and thus it is
difficult to draw definitive conclusions from this finding.
Strengths of our study include the use of large data-
bases with survival information from a broad sampling
of each country, allowing for evaluation of survival and
subgroup analysis of this rare tumor and decreasing the
risk that survival differences between individual parts of
the country will unduly influence the impression of sur-
vival in the country overall. Use of population-level data
provides a more realistic picture of diffusion of changes
in the standard of care and of how probable a patient
with a given disease in the general population is to sur-
vive in contrast to data provided by clinical trials which
tend to present the best-case scenario with respect to
survival and may not be realistic for the general popula-
tion. Additionally, the use of period analysis and
modelled period analysis provides the most up-to-date
estimates of survival possible.
In interpreting our results, several limitations should
also be considered. First, despite the large population
bases, the relative rarity of CML limits our ability todetect minor differences in survival. Second, in the ab-
sence of a national death index in Germany, most cancer
registries rely on record linkage with vital statistics from
the (federal) state that they cover and may miss deaths
among patients who move out of the state. Nevertheless,
previous validation studies have suggested potential
overestimation of survival due to deaths missed by mi-
gration to be very small [21]. Third, data on chemother-
apy administration or oral therapeutic medications is
available in neither the SEER nor the German database
and therefore we can not make definitive statements
about how use of specific medications affects survival.
Fourth, there is some evidence that survival estimates
from the SEER database may be higher than survival in
the US population in general [23], so some caution is
necessary when comparing survival in the two countries.
Fifth, because some of the German databases are fairly
new, the analysis is restricted to 5-year survival which
prohibited analysis of longer survival, such as 10-year
relative survival, that is of particular interest in CML.
Additionally, data in this project were available only
through 2006 so newer developments since the intro-
duction of second-generation TKIs are not yet captured.
Finally and most significantly, several of the newer
German registries are still in the build-up phase and the
proportion of cases identified by DCO is still rather high
in some of these registries. Exclusion of these DCO
cases in the analysis may lead to some overestimation of
survival [37,38]. Exploring the potential magnitude of
such overestimation by plausibility ranges [39] suggests
that true survival in Germany might be up to a few per-
centage points lower than estimated. Thus, the survival
gap between Germany and the US might be even some-
what larger than suggested by the available data, espe-
cially in the older age groups in which DCO proportions
are highest. This suggestion was supported by sensitivity
analyses excluding cancer registries with DCO propor-
tions >12% which yielded somewhat lower survival esti-
mates in Germany, especially in age group 60–69 years.
Additionally, the large proportion of DCO cases in older
patients (age 70+) from Germany precluded sufficiently
reliable analyses for this age group which means that no
conclusions can be drawn with respect to this important
segment of the population.
In summary, 5-year relative survival for patients with
CML is high, especially for younger patients, in both the
US and Germany, although survival is higher in the US
for some age groups. Survival is improving in both coun-
tries, with greater improvement seen among middle-
aged patients (age 60–69) in the US, perhaps suggesting
improved uptake of TKIs among these patients. Never-
theless, prognosis in this age group continues to lag
behind prognosis in younger patients. Further emphasis
on treatment of middle aged patients with CML and
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CML may continue to improve survival in this age
group.
Competing interests
The authors have no conflicts of interest to disclose.
Authors’ contributions
DP, BB, and HB designed the research. LJ performed the research. All authors
contributed to the analysis of the data and review of the manuscript. DP wrote
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
Members of the GEKID Cancer Survival Working Group: Karla Geiss, Martin
Meyer (Cancer Registry of Bavaria), Andrea Eberle, Sabine Luttmann (Cancer
Registry of Bremen), Roland Stabenow (Cancer Registry of Berlin and the
New Federal States), Stefan Hentschel, Alice Nennecke (Cancer Registry of
Hamburg); Joachim Kieschke, Eunice Sirri (Cancer Registry of Lower Saxony),
Bernd Holleczek (Saarland Cancer Registry), Katharina Emrich (Cancer Registry
of Rhineland-Palatinate), Hiltraud Kajüter, Volkmar Mattauch (Cancer Registry
of North Rhine-Westphalia), Alexander Katalinic (Cancer Registry of
Schleswig-Holstein), Benjamin Barnes, Klaus Kraywinkel (Robert Koch Institute,
Berlin), Hermann Brenner, Adam Gondos, Lina Jansen (DKFZ).
This work was supported in part by a grant from the German Cancer Aid
(Deutsche Krebshilfe, no. 108257) and a visiting scientist grant from the DKFZ.
Author details
1Division of Clinical Epidemiology and Aging Research, German Cancer
Research Center (DKFZ), Heidelberg, Germany. 2Cardeza Foundation and
Division of Hematology, Department of Medicine, Thomas Jefferson
University, 1015 Chestnut Street Suite 1321, Philadelphia, PA 19107, USA.
3National Center for Cancer Registry Data, Robert Koch Institute, Berlin,
Germany. 4Institute of Cancer Epidemiology, University of Lübeck, Lübeck,
Germany. 5Cancer Registry of Rhineland-Palatinate, Institute for Medical
Biostatistics, Epidemiology and Informatics, University Medical Center,
Johannes Gutenberg University Mainz, Mainz, Germany. 6Hamburg Cancer
Registry, Authority for Health and Consumer Protection, Hamburg, Germany.
7Saarland Cancer Registry, Saarbrücken, Germany. 8German Cancer
Consortium (DKTK), Heidelberg, Germany.
Received: 10 July 2013 Accepted: 10 September 2013
Published: 16 September 2013
References
1. Meyskens FL Jr, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W,
Hynes H: Effects of vitamin A on survival in patients with chronic
myelogenous leukemia: a SWOG randomized trial. Leuk Res 1995,
19(9):605–612.
2. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of
busulfan and hydroxyurea in chronic myelogenous leukemia:
prolongation of survival by hydroxyurea. The German CML Study Group.
Blood 1993, 82(2):398–407.
3. Pulte D, Gondos A, Redaniel MT, Brenner H: Survival of patients with
chronic myelocytic leukemia: comparisons of estimates from clinical trial
settings and population-based cancer registries. Oncologist 2011,
16(5):663–671.
4. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of
interferon-alpha with busulfan and hydroxyurea in chronic myelogenous
leukemia. The German CML Study Group. Blood 1994, 84(12):4064–4077.
5. Guilhot F, Chastang C, Michallet M, et al: Interferon alfa-2b combined with
cytarabine versus interferon alone in chronic myelogenous leukemia.
French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997,
337(4):223–229.
6. Clift RA, Bucknew CD, Thomas ED, et al: Marrow transplantation for
chronic myeloid leukemia: a randomized study comparing
cyclophosphamide and total body irradiation with busulfan and
cyclophosphamide. Blood 1994, 84(6):2036–2043.
7. Gale RP, Hehlmann R, Zhang MJ, et al: Survival with bone marrow
transplantation versus hydroxyurea or interferon for chronic myelogenous
leukemia. The German CML Study Group. Blood 1998, 91(5):1810–1819.8. Druker BJ, Lydon NB: Lessons learned from the development of an abl
tyrosine kinase inhitior for chronic myelogenous leukemia. J Clin Invest 2000,
105(1):3–7.
9. European Medicines Agency (EMEA): European public assessment report
(EPAR) Glivec: EPAR summary for the public. EMEA/H/C 2009, 406:3.
10. Cohen MH, Williams G, Johnson JR, et al: Approval summary for imatinib
mesylate capsules in the treatment of chronic myelogenous leukemia.
Clin Cancer Res 2002, 8:935–942.
11. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients
receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006,
355(23):2408–2417.
12. Hochhaus A, O’Brien SG, Guilhot F, et al: Six-year follow-up of patients
receiving imatinib for the first-line treatment of chronic myeloid
leukemia. Leukemia 2009, 23(6):1054–1061.
13. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from
a randomized phase 3 trial (DASISION). Blood 2012, 119(5):1123–1129.
14. Kantarjian HM, Hochhaus A, Saglio G, et al: Nilotinib versus imatinib for the
treatment of patients with newly diagnosed chronic phase, Philadelphia
chromosome positive, chronic myeloid leukaemia: 24-month minimum
follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011,
12(9):841–851.
15. Brenner H, Gondos A, Pulte D: Recent trends in long-term survival of
patients with chronic myelocytic leukemia: disclosing the impact of
advances in therapy on the population level. Haematologica 2008,
93(10):1544–1549.
16. Brenner H, Gondos A, Pulte D: Long-term survival in chronic myelocytic
leukemia after a first primary malignancy. Leuk Res 2009, 33(12):1604–1608.
17. Wiggins CL, Harlan LC, Nelson HE, et al: Age disparity in the dissemination
of imatinib for treating chronic myeloid leukemia. M J Med 2010,
123(8):1–9. 764.e.
18. Lamvik J, Brinch L, Dahl IM, et al: Chronic myeloid leukemia in health regions
1,3,4, and 5 during the period 1990–96. Tidsskr Nor Laegeforen 1999,
119(12):1733–1736.
19. Corm S, Roche L, Micol JB, et al: Changes in the dynamics of the excess
mortality rate in chronic phase-chronic myeloid leukemia over 1990–2007:
a population study. Blood 2011, 118(16):4331–4337.
20. Björkholm M, Ohm L, Eloranta S, et al: Success story of targeted therapy in
chronic myeloid leukemia: a population-based study of patients diagnosed
in Sweden from 1973 to 2008. J Clin Oncol 2011, 29(18):2514–2520.
21. Hiripi E, Gondos A, Emrich K, et al: Survival from common and rare cancers in
Germany in the early 21st century. Ann Oncol 2012, 23(2):472–479.
22. Surveillance, Epidemiology, and End Results (SEER): Program (www.seer.
cancer.gov) Research Data (1973–2008), National Cancer Institute, DCCPS,
Surveillance Research Program, Cancer Statistics Branch, released April 2011,
based on the November 2010 submission..
23. Mariotto A, Capocaccia R, Verdecchia A, et al: Projecting SEER cancer survival
rates to the US: an ecological regression approach. Cancer Causes Control 2002,
13:101–111.
24. Brenner H, Gefeller O, Hakulinen T: Period analysis for up-to-date cancer
survival data: theory, empirical evaluation, computational realization and
applications. Eur J Cancer 2004, 40:326–335.
25. Brenner H, Gefeller O: An alternative approach to monitoring cancer
patient survival. Cancer 1996, 78(9):2004–2010.
26. Brenner H, Soederman B, Hakulinen T: Use of period analysis for providing
more up-to-date estimates of long-term survival rates: empirical evaluation
among 370,000 cancer patients in Finland. Int J Epidemiol 2002,
31(2):456–462.
27. Brenner H, Hakulinen T: Up-to-date long-term survival curves of patients
with cancer by period analysis. J Clin Oncol 2002, 20(3):826–832.
28. Sokel JE, Baccarni M, Tura S, et al: Prognostic discrimination among
younger patients with chronic granulocytic leukemia: relevance to bone
marrow transplantation. Blood 1985, 66(6):1352–1357.
29. Brenner H, Hakulinen T: Up-to-date and precise estimates of cancer
patient survival: model-based period analysis. Am J Epidemiol 2006,
164(7):689–696.
30. Ederer F: HH. Instructions to IBM 650 programmers in processing survival
computations. Bethesda, MD: National Cancer Institute; 1959.
31. Arias E: United States life tables, 2000. Natl Vit Stat Rep 2002:1–39.
32. Brenner H, Gefeller O, Hakulinen T: A computer program for period
analysis of cancer patients survival. Eur J Cancer 2002, 38:690–695.
Pulte et al. Journal of Hematology & Oncology 2013, 6:70 Page 7 of 7
http://www.jhoonline.org/content/6/1/7033. Cortes J, Talpaz M, O’Brien S, et al: Effects of age on prognosis with imatinib
mesylate therapy for patients with Philadelphia chromosome-positive
chronic myelogenous leukemia. Cancer 2003, 98(6):1105–1113.
34. Gugliotta G, Castagnetti F, Palandri F, et al: Frontline imatinib treatment of
chronic myeloid leukemia: no impact of age on outcome, a survey by
the GIMEMA CML Working Party. Blood 2011, 117(21):5591–5599.
35. Joensson B, Wilking N: A global comparison regarding patient access to
cancer drugs. Ann Oncol 2007, 18(Suppl 3):iii1–iii77.
36. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarni M, Lokey L:
Diagnosis and management of chronic myeloid leukemia: a survey of
American and European practice patterns. Cancer 2007, 109(7):1365–1375.
37. Berrino F, Esteve J, Coleman MP: Basic issues in estimating and comparing
the survival of cancer patients. IARC Sci Publ 1995, 132:1–14.
38. Robinson D, Sankila R, Hakulinen T, Moller H: Interpreting international
comparisons of cancer survival: the effects of incomplete registration
and the presence of death certificate only cases on survival estimates.
Eur J Cancer 2007, 43(5):909–913.
39. Brenner H, Holleczek B: Deriving valid population-based cancer survival
estimates in the presence of nonnegligible proportions of cancers
notified by death certificate only. Cancer Epidemiol Biomarkers Prev 2011,
20(12):2480–2486.
doi:10.1186/1756-8722-6-70
Cite this article as: Pulte et al.: Population level survival of patients with
chronic myelocytic leukemia in Germany compared to the US in the
early 21st century. Journal of Hematology & Oncology 2013 6:70.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
